{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:56:13Z","timestamp":1790834173904,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo (ANID), Chile","award":["15130011"],"award-info":[{"award-number":["15130011"]}]},{"name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo (ANID), Chile","award":["1181097"],"award-info":[{"award-number":["1181097"]}]},{"name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo (ANID), Chile","award":["1211270"],"award-info":[{"award-number":["1211270"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Pulmonary artery hypertension (PAH) is a chronic and progressive disease. Although current therapy has improved the disease prognosis, PAH has a poor survival rate. The key feature leading to disease progression and death is right ventricular (RV) failure. Methods and results: We assessed the role of trimetazidine, a fatty acid beta-oxidation (FAO) inhibitor, in right ventricular function, remodeling, and functional class in PAH patients, with a placebo-controlled double-blind, case-crossover trial. Twenty-seven PAH subjects were enrolled, randomized, and assigned to trimetazidine or placebo for three months and then reallocated to the other study arm. The primary endpoint was RV morphology and function change after three months of treatment. Secondary endpoints were the change in exercise capacity assessed by a 6 min walk test after three months of treatment and the change in pro-BNP and Galectin-3 plasma levels after three months. Trimetazidine use was safe and well-tolerated. After three months of treatment, patients in the trimetazidine group showed a small but significant reduction of RV diastolic area, and a substantial increase in the 6 min walk distance (418 vs. 438 mt, p = 0.023), without significant changes in biomarkers. Conclusions: A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.<\/jats:p>","DOI":"10.3390\/jcm12041571","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T04:51:46Z","timestamp":1676523106000},"page":"1571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial"],"prefix":"10.3390","volume":"12","author":[{"given":"Hugo E.","family":"Verdejo","sequence":"first","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago 8330077, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-3194","authenticated-orcid":false,"given":"Adolfo","family":"Rojas","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Qu\u00edmicas y Farmac\u00e9uticas & Facultad de Medicina, Universidad de Chile, Santiago 8380492, Chile"},{"name":"Department of Internal Medicine, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"L\u00f3pez-Crisosto","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago 8330077, Chile"},{"name":"Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Qu\u00edmicas y Farmac\u00e9uticas & Facultad de Medicina, Universidad de Chile, Santiago 8380492, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Baraona","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago 8330077, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago 8330077, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-9381","authenticated-orcid":false,"given":"Vinicius","family":"Maracaja-Coutinho","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Qu\u00edmicas y Farmac\u00e9uticas & Facultad de Medicina, Universidad de Chile, Santiago 8380492, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Chiong","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Qu\u00edmicas y Farmac\u00e9uticas & Facultad de Medicina, Universidad de Chile, Santiago 8380492, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-1483","authenticated-orcid":false,"given":"Sergio","family":"Lavandero","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Qu\u00edmicas y Farmac\u00e9uticas & Facultad de Medicina, Universidad de Chile, Santiago 8380492, Chile"},{"name":"Department of Internal Medicine, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo F.","family":"Castro","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago 8330077, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Galie","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"166200","DOI":"10.1016\/j.bbadis.2021.166200","article-title":"Novel molecular insights and public omics data in pulmonary hypertension","volume":"1867","author":"Sepulveda","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1172\/JCI120847","article-title":"Mitochondrial metabolism in pulmonary hypertension: Beyond mountains there are mountains","volume":"128","author":"Culley","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/hr.2015.153","article-title":"Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis","volume":"39","author":"Sun","year":"2016","journal-title":"Hypertens. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44ra58","DOI":"10.1126\/scitranslmed.3001327","article-title":"Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension","volume":"2","author":"Sutendra","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","article-title":"Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle\u2019s cycle","volume":"90","author":"Fang","year":"2012","journal-title":"J. Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jss.2006.05.003","article-title":"A new imputation method for small software project data sets","volume":"80","author":"Song","year":"2007","journal-title":"J. Syst. Softw."},{"key":"ref_10","first-page":"1","article-title":"Imputation with the R Package VIM","volume":"74","author":"Kowarik","year":"2016","journal-title":"J. Syst. Softw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1152\/japplphysiol.00283.2015","article-title":"Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension","volume":"119","author":"Stenmark","year":"2015","journal-title":"J. Appl. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2005.02.065","article-title":"Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol","volume":"45","author":"Oikawa","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI23203","article-title":"Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension","volume":"115","author":"McMurtry","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2353\/ajpath.2010.090832","article-title":"Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells","volume":"176","author":"Fijalkowska","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/2045-8932.109960","article-title":"Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension","volume":"3","author":"Archer","year":"2013","journal-title":"Pulm. Circ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00109-009-0524-6","article-title":"The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle","volume":"88","author":"Piao","year":"2010","journal-title":"J. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/cvr\/cvx148","article-title":"Treatment strategies for the right heart in pulmonary hypertension","volume":"113","author":"Westerhof","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/HJR.0b013e328304feec","article-title":"Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation","volume":"15","author":"Belardinelli","year":"2008","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2019.05.063","article-title":"Trimetazidine in cardiovascular medicine","volume":"293","author":"Marzilli","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/147323000503300602","article-title":"Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale","volume":"33","author":"Bayram","year":"2005","journal-title":"J. Int. Med. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehm071","article-title":"Trimetazidine improves endothelial dysfunction in chronic heart failure: An antioxidant effect","volume":"28","author":"Belardinelli","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.05.005","article-title":"Oxidative and nitrosative signalling in pulmonary arterial hypertension\u2014Implications for development of novel therapies","volume":"165","author":"Hansen","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/ars.2018.7705","article-title":"Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension","volume":"31","author":"Suliman","year":"2019","journal-title":"Antioxid. Redox. Signal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bcp.2014.07.022","article-title":"Trimetazidine prevents palmitate-induced mitochondrial fission and dysfunction in cultured cardiomyocytes","volume":"91","author":"Kuzmicic","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.bbadis.2017.07.018","article-title":"Inhibition of mitochondrial fission prevents hypoxia-induced metabolic shift and cellular proliferation of pulmonary arterial smooth muscle cells","volume":"1863","author":"Parra","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1097\/MJT.0000000000001430","article-title":"Trimetazidine Therapy in Coronary Artery Disease: The Impact on Oxidative Stress, Inflammation, Endothelial Dysfunction, and Long-Term Prognosis","volume":"28","author":"Bobescu","year":"2021","journal-title":"Am. J. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100932","DOI":"10.1016\/j.cpcardiol.2021.100932","article-title":"Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment","volume":"47","author":"Avagimyan","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/07853890.2021.1925147","article-title":"Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice","volume":"53","author":"Yang","year":"2021","journal-title":"Ann. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"H1122","DOI":"10.1152\/ajpheart.2001.281.3.H1122","article-title":"Triglycerides impair postischemic recovery in isolated hearts: Roles of endothelin-1 and trimetazidine","volume":"281","author":"Monti","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2013.03.027","article-title":"Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: Involvement of antioxidation and Akt\/eNOS signaling pathways","volume":"707","author":"Wu","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yjmcc.2021.01.003","article-title":"MicroRNA-21 regulates right ventricular remodeling secondary to pulmonary arterial pressure overload","volume":"154","author":"Chang","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3892\/ijmm.2012.1078","article-title":"Trimetazidine improves right ventricular function by increasing miR-21 expression","volume":"30","author":"Liu","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kim, S., Yu, Y.M., Kwon, J., Jeong, K.H., Lee, J.S., and Lee, E. (2020). Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study. Int. J. Environ. Res. Public. Health, 17.","DOI":"10.3390\/ijerph17197256"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/4\/1571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:37:55Z","timestamp":1760121475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/4\/1571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12041571"],"URL":"https:\/\/doi.org\/10.3390\/jcm12041571","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}